Insulin pump catheter anti-blocking structure

Abstract

The utility model provides an insulin pump catheter anti-blocking structure, which belongs to the technical field of medical instruments, and comprises a main body and a catheter, the catheter is arranged at the end part of the main body, a main cavity and an auxiliary cavity are arranged in the catheter, the main cavity and the auxiliary cavity are arranged in parallel, and the main cavity is communicated with the auxiliary cavity. The main cavity is used for insulin injection, an elastic film is arranged in the auxiliary cavity, the main cavity and the auxiliary cavity are connected with a pump body of the main body through a pump body connector, and the far end of the main cavity and the far end of the auxiliary cavity are jointly connected to a subcutaneous connector; the length of the main cavity is larger than that of the auxiliary cavity and smaller than twice that of the auxiliary cavity, the cross section of the main cavity and the cross section of the auxiliary cavity are both circular, the distance between the circle centers of the main cavity and the circle center of the auxiliary cavity ranges from 0.5 mm to 2 mm, the problem that a catheter of a traditional insulin pump is prone to being blocked is solved, and the use reliability of the insulin pump is improved.

Description

Technical Field

[0001] The utility model belongs to the technical field of medical devices, and in particular relates to an anti-blocking structure for an insulin pump catheter. Background Art

[0002] An insulin pump is an advanced diabetes treatment device that mimics the function of the human pancreas and effectively controls blood sugar levels by continuously and accurately infusing insulin into the patient's body. An insulin pump consists of a pump body, a small syringe, an infusion tube, and a subcutaneous catheter connected to it. The pump body is equipped with a battery-driven motor that pushes the insulin in the syringe into the infusion tube in small doses, continuously or on demand, through precise control. The guide needle at the front end of the infusion tube is inserted into the patient's subcutaneous tissue (usually in the abdomen) through a needle injector to form a stable insulin delivery channel.

[0003] Traditional insulin pump catheters are usually made of medical-grade materials with good biocompatibility and chemical stability to ensure long-term safe use in patients. However, although insulin pumps have improved the treatment effect and quality of life of diabetic patients, the problem of catheter blockage has always been an important problem that plagues patients and medical workers during use. The main causes of catheter blockage include: Insulin crystallization: Insulin is easy to form crystals under specific conditions (such as low temperature, high concentration, pH change, etc.), especially when it is stationary for a long time in the catheter or the flow rate is too slow, the crystals are easy to deposit on the tube wall or aggregate to form a blockage. Blood clot formation: Blood components in the subcutaneous tissue may interact with insulin or catheter materials to cause local thrombosis, especially when the patient has abnormal coagulation function or uses anticoagulants, blood clots become the main source of catheter blockage. Skin debris or other foreign matter: During intubation, skin debris, hair follicle oil, sebaceous gland secretions, etc. may be brought into the catheter. These substances accumulate in the tube and interact with insulin, increasing the risk of blockage. Catheter inner surface properties: Roughness, lack of hydrophilicity or surface adsorption characteristics of the catheter inner wall may cause insulin molecules to adhere and aggregate more easily, promoting crystallization and blockage. Utility Model Content

[0004] In view of this, the utility model provides an anti-clogging structure for an insulin pump catheter. By designing a double-lumen infusion catheter and a built-in elastic film, the circulating flow in the secondary cavity can continuously disturb the insulin in the main cavity to prevent crystal deposition. At the same time, the physical scraping effect of the film is utilized to solve the problem that traditional insulin pump catheters are easily clogged.

[0005] The utility model is achieved in this way:

[0006] The utility model provides an insulin pump catheter anti-blocking structure, comprising a main body and a catheter, wherein the catheter is arranged at the end of the main body, wherein a main cavity and a secondary cavity are arranged in parallel inside the catheter, the main cavity is used for insulin injection, an elastic film is built in the secondary cavity, the main cavity and the secondary cavity are connected to the pump body of the main body through a pump body interface, and the distal ends of the main cavity and the secondary cavity are connected to a subcutaneous interface together;

[0007] Wherein, the length of the main cavity is greater than the length of the secondary cavity, and less than twice the length of the secondary cavity.

[0008] On the basis of the above technical solution, the anti-blocking structure of an insulin pump catheter of the utility model can also be improved as follows:

[0009] Wherein, the cross sections of the main cavity and the auxiliary cavity are both circular, and the distance between the centers of the main cavity and the auxiliary cavity is between 0.5 mm and 2 mm.

[0010] Furthermore, the ratio of the inner diameters of the main cavity to the auxiliary cavity is in the range of 3 mm to 6 mm.

[0011] The beneficial effect of adopting the above-mentioned improvement is that the inner diameter of the main cavity is at least three times, but not more than six times, of the inner diameter of the main cavity. Such a size configuration is intended to ensure that the circulation flow generated in the secondary cavity is moderate, which can effectively disturb the insulin in the main cavity and prevent crystal deposition, while not excessively affecting the insulin delivery efficiency of the main cavity.

[0012] Furthermore, the elastic film is an annular structure, whose inner diameter is equal to the inner diameter of the auxiliary cavity, and whose outer diameter is equal to the inner diameter of the auxiliary cavity plus a preset thickness.

[0013] Furthermore, the preset thickness is between 0.1 mm and 0.5 mm.

[0014] Furthermore, the pump body interface is provided with a main cavity communication port and a secondary cavity communication port, the main cavity communication port is communicated with the main cavity, and the secondary cavity communication port is communicated with the secondary cavity.

[0015] Furthermore, the main cavity communication port and the auxiliary cavity communication port are staggered in the axial direction by a distance between 10 mm and 30 mm.

[0016] Furthermore, the subcutaneous interface is provided with a confluence portion, and the confluence portion is provided with a geometric transition, and the geometric transition includes a cone and an arc.

[0017] The beneficial effects of adopting the above-mentioned improvement scheme are as follows: a gradual transition structure is specially designed in the confluence of the main and secondary cavities, which is intended to ensure that the liquids in the main cavity and the secondary cavity can smoothly and gradually integrate and flow when they merge into the subcutaneous tissue, avoiding unnecessary impact or discomfort to the subcutaneous tissue due to sudden changes in flow rate and pressure. The gradual transition structure adopts a continuously changing geometric shape, such as a conical, arc-shaped or diffuser-like design, so that the inner diameter of the intersection of the main cavity and the secondary cavity gradually increases until it matches the caliber of the final subcutaneous interface. This gradually expanding channel design is conducive to the natural decrease of the liquid flow rate and reduces sudden changes in fluid dynamics.

[0018] Furthermore, the elastic film is provided with a plurality of holes, the holes are arranged in an array, and the diameter of the holes is between 0.1 mm and 0.3 mm.

[0019] Furthermore, the elastic film is made of medical silicone rubber or polyurethane.

[0020] Compared with the prior art, the beneficial effects of the insulin pump catheter anti-blocking structure provided by the utility model are:

[0021] Active anti-blocking mechanism: The secondary chamber in the dual-chamber structure has an elastic film built into it, which is driven by the pump body to generate circulating flow. This design breaks through the limitation of traditional catheters that rely only on a single infusion channel and introduces an active anti-blocking mechanism. The circulating fluid in the secondary chamber continuously disturbs the insulin in the main chamber, effectively inhibiting the formation and deposition of crystals, and reducing the probability of blockage caused by insulin crystallization;

[0022] Physical scraping and removal: The elastic film physically scrapes the inner wall of the main cavity during the circulation process, which can promptly remove the tiny crystals that have formed and prevent them from agglomerating, further ensuring the unobstructed flow of the catheter. This physical removal method does not require additional energy or complex control systems, and is both energy-saving and reliable;

[0023] Gentle infusion protects subcutaneous tissue: A gradual transition structure is provided in the confluence of the main and secondary cavities to ensure that the liquid in the main and secondary cavities can smoothly and gradually integrate and flow when they merge into the subcutaneous tissue, avoiding unnecessary impact or discomfort to the subcutaneous tissue due to sudden changes in flow rate and pressure. This design improves the comfort of infusion, reduces adverse reactions such as subcutaneous nodules, redness and swelling, and improves the quality of life of patients;

[0024] Optimize insulin delivery efficiency: By reasonably setting the inner diameter ratio, length ratio and circulation flow parameters of the main cavity and the secondary cavity, the utility model ensures that the circulation flow of the secondary cavity effectively disturbs the insulin in the main cavity, while not affecting the insulin delivery efficiency of the main cavity. This allows insulin to be stably and continuously delivered to the patient at a predetermined rate, ensuring the accuracy of blood sugar control. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] In order to more clearly illustrate the technical solutions of the embodiments of the utility model, the drawings required for use in the description of the embodiments of the utility model will be briefly introduced below. Obviously, the drawings in the following description are only some embodiments of the utility model. For ordinary technicians in this field, other drawings can be obtained based on these drawings without creative work.

[0026] Figure 1 This is an example diagram of an anti-blocking structure for an insulin pump catheter;

[0027] Figure 2 A perspective view of a pump body interface of an insulin pump catheter anti-clogging structure;

[0028] Figure 3 A perspective view of an insulin pump catheter anti-blockage structure catheter;

[0029] In the accompanying drawings, the components represented by the reference numerals are listed as follows:

[0030] 10. Main body; 11. Pump body interface; 111. Main cavity communication port; 112. Sub-cavity communication port; 20. Catheter; 21. Main cavity; 22. Sub-cavity; 221. Elastic film; 30. Subcutaneous interface. DETAILED DESCRIPTION

[0031] In order to make the purpose, technical solution and advantages of the implementation mode of the present invention clearer, the technical solution in the implementation mode of the present invention will be clearly and completely described below in conjunction with the accompanying drawings in the implementation mode of the present invention.

[0032] like Figure 1 , Figure 2 , Figure 3 As shown, it is a first embodiment of an insulin pump catheter anti-blocking structure provided by the utility model. In this embodiment, it includes a main body 10 and a catheter 20. The catheter 20 is arranged at the end of the main body 10, wherein a main cavity 21 and a secondary cavity 22 are arranged inside the catheter 20. The main cavity 21 and the secondary cavity 22 are arranged in parallel. The main cavity 21 is used for insulin injection, and an elastic film 221 is built in the secondary cavity 22. The main cavity 21 and the secondary cavity 22 are connected to the pump body of the main body 10 through the pump body interface 11, and the distal ends of the main cavity 21 and the secondary cavity 22 are connected to the subcutaneous interface 30 together;

[0033] The length of the main cavity 21 is greater than the length of the auxiliary cavity 22 , and less than twice the length of the auxiliary cavity 22 .

[0034] The main cavity and the secondary cavity are closely arranged along the axial direction of the catheter (i.e., the infusion direction), and the two maintain the same extension direction in the longitudinal direction of the catheter. This parallel arrangement ensures that the insulin infusion in the main cavity and the circulation flow in the secondary cavity can be carried out synchronously, and the spatial layout is compact and efficient.

[0035] The main cavity and the secondary cavity are connected or isolated through specific structures at specific parts of the catheter. At the end close to the pump body interface, the main cavity and the secondary cavity are connected to the pump body through their respective connecting ports to achieve the input of insulin (main cavity) and the drive of circulating fluid (secondary cavity). At the subcutaneous interface far away from the pump body, the liquids of the main and secondary cavities merge together and flow into the subcutaneous tissue through a gradual transition structure. In the middle part of the catheter, the main cavity and the secondary cavity are strictly physically isolated to ensure that insulin and circulating fluid do not mix with each other.

[0036] Among them, in the above technical solution, the cross-sections of the main cavity 21 and the auxiliary cavity 22 are both circular, and the distance between the centers of the main cavity 21 and the auxiliary cavity 22 is between 0.5 mm and 2 mm.

[0037] Furthermore, in the above technical solution, the ratio of the inner diameters of the main cavity 21 and the auxiliary cavity 22 is in the range of 3 mm to 6 mm.

[0038] Furthermore, in the above technical solution, the elastic film 221 is an annular structure, whose inner diameter is equal to the inner diameter of the auxiliary cavity 22, and whose outer diameter is equal to the inner diameter of the auxiliary cavity 22 plus a preset thickness.

[0039] The elastic film is fixed on the inner wall of the auxiliary cavity to prevent displacement or falling off during the circulation process. The fixing method can be embedded, adhesive or snap-on, etc. to ensure a reliable sealing connection between the film and the inner wall of the auxiliary cavity, while not hindering the vibration of the film and the flow of the circulating fluid.

[0040] The thickness of the elastic film is non-uniformly distributed along the radial direction, and the thickness in the middle of the film is greater than the thickness at the edge, so as to improve the stability of the film in the circulation flow.

[0041] Furthermore, in the above technical solution, the preset thickness is between 0.1 mm and 0.5 mm.

[0042] Furthermore, in the above technical solution, the pump body interface 11 is provided with a main cavity communication port and a sub-cavity communication port, the main cavity communication port is communicated with the main cavity 21 , and the sub-cavity communication port is communicated with the sub-cavity 22 .

[0043] Furthermore, in the above technical solution, the main cavity communication port and the auxiliary cavity communication port are staggered along the axial direction by a distance between 10 mm and 30 mm.

[0044] Furthermore, in the above technical solution, the subcutaneous interface 30 is provided with a confluence portion, and the confluence portion is provided with a geometric transition, and the geometric transition includes a cone and an arc.

[0045] Furthermore, in the above technical solution, the elastic film 221 is provided with a plurality of holes, which are arranged in an array, and the hole diameters are between 0.1 mm and 0.3 mm.

[0046] Furthermore, in the above technical solution, the elastic film 221 is made of medical silicone rubber or polyurethane.

[0047] The elastic film should be made of medical grade materials with excellent elasticity, such as medical silicone rubber or polyurethane. These materials should have good biocompatibility, corrosion resistance, fatigue resistance, and long-term stability in insulin solutions. In addition, the film material should have appropriate hardness and flexibility to ensure that it can generate sufficient vibration to remove crystals during circulation and maintain good durability.

[0048] Specifically, the principle of the utility model is:

[0049] Dual-chamber structure design: The main chamber is responsible for the regular infusion of insulin, while the secondary chamber is driven by the pump body to generate circulating flow. The main and secondary chambers are set in parallel to form a specific spacing and diameter ratio to ensure that the circulating fluid in the secondary chamber can effectively disturb the insulin in the main chamber;

[0050] Application of elastic film: The elastic film built into the sub-chamber vibrates under the drive of the pump body to form a circulating flow. The physical scraping action of the film can remove the tiny crystals that have formed on the inner wall of the main chamber to prevent their accumulation and blockage. The material, thickness, pore size and other parameters of the film have been carefully designed to ensure its stability, durability and physical cleaning effect during the circulation process;

[0051] Gradual transition structure: The gradual transition structure in the confluence of the main and secondary cavities, through geometric transition, streamlined guidance or porous dispersion, enables the liquid in the main cavity and the secondary cavity to flow smoothly and gradually when they merge into the subcutaneous tissue, avoiding impact on the subcutaneous tissue. This design ensures the gentleness and safety of insulin infusion.

Claims

1. An insulin pump catheter anti-blocking structure, comprising a main body (10) and a catheter (20), wherein the catheter (20) is arranged at the end of the main body (10), characterized in that: The catheter (20) is provided with a main cavity (21) and a secondary cavity (22), the main cavity (21) and the secondary cavity (22) are arranged in parallel, the main cavity (21) is used for insulin injection, the secondary cavity (22) has an elastic film (221) built in, the main cavity (21) and the secondary cavity (22) are connected to the pump body of the main body (10) through the pump body interface (11), and the distal ends of the main cavity (21) and the secondary cavity (22) are connected to the subcutaneous interface (30) together; Wherein, the length of the main cavity (21) is greater than the length of the secondary cavity (22), and less than twice the length of the secondary cavity (22).

2. The insulin pump catheter anti-blocking structure according to claim 1, characterized in that: The cross sections of the main cavity (21) and the auxiliary cavity (22) are both circular, and the distance between the centers of the main cavity (21) and the auxiliary cavity (22) is between 0.5 mm and 2 mm.

3. The insulin pump catheter anti-blocking structure according to claim 2, characterized in that: The ratio of the inner diameters of the main cavity (21) to the inner diameters of the secondary cavity (22) is in the range of 3 mm to 6 mm.

4. The insulin pump catheter anti-blocking structure according to claim 3, characterized in that: The elastic film (221) is an annular structure, the inner diameter of which is equal to the inner diameter of the auxiliary cavity (22), and the outer diameter of which is equal to the inner diameter of the auxiliary cavity (22) plus a preset thickness.

5. The insulin pump catheter anti-blocking structure according to claim 4, characterized in that: The preset thickness is between 0.1 mm and 0.5 mm.

6. The insulin pump catheter anti-blocking structure according to claim 5, characterized in that: The pump body interface (11) is provided with a main chamber communication port (111) and a secondary chamber communication port (112); the main chamber communication port (111) is in communication with the main chamber (21), and the secondary chamber communication port (112) is in communication with the secondary chamber (22).

7. The insulin pump catheter anti-blocking structure according to claim 6, characterized in that: The main cavity communication port (111) and the auxiliary cavity communication port (112) are staggered in the axial direction by a distance between 10 mm and 30 mm.

8. The insulin pump catheter anti-blocking structure according to claim 7, characterized in that: The subcutaneous interface (30) is provided with a confluence portion, and the confluence portion is provided with a geometric transition, wherein the geometric transition includes a cone and an arc.

9. The insulin pump catheter anti-blocking structure according to claim 8, characterized in that: The elastic film (221) is provided with a plurality of holes, which are arranged in an array, and the diameter of the holes is between 0.1 mm and 0.3 mm.

10. The insulin pump catheter anti-blocking structure according to claim 9, characterized in that: The elastic film (221) is made of medical silicone rubber or polyurethane.

Images